Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.9 SEK | +5.68% | +22.43% | +81.13% |
18/04 | Diamyd Medical Raises SEK57 Million in Rights Issue | MT |
12/04 | Recruitment Milestone Reaches in Diamyd® Phase 3 Trial | CI |
Sales 2024 * | 3M 274K 22.86M | Sales 2025 * | 3M 274K 22.86M | Capitalization | 1.22B 112M 9.31B |
---|---|---|---|---|---|
Net income 2024 * | -133M -12.16M -1.01B | Net income 2025 * | -165M -15.08M -1.26B | EV / Sales 2024 * | 361 x |
Net cash position 2024 * | 139M 12.71M 1.06B | Net cash position 2025 * | 30M 2.74M 229M | EV / Sales 2025 * | 397 x |
P/E ratio 2024 * |
-8.95
x | P/E ratio 2025 * |
-7.21
x | Employees | 26 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 72.91% |
Latest transcript on Diamyd Medical AB
1 day | +5.68% | ||
1 week | +22.43% | ||
Current month | +13.55% | ||
1 month | +12.05% | ||
3 months | +46.73% | ||
6 months | +74.74% | ||
Current year | +81.13% |
Managers | Title | Age | Since |
---|---|---|---|
Ulf Hannelius
CEO | Chief Executive Officer | 49 | 10/16/10 |
Founder | 83 | 01/96/01 | |
Anna Styrud
DFI | Director of Finance/CFO | 63 | 01/10/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 83 | 01/96/01 | |
Director/Board Member | 63 | 01/12/01 | |
Director/Board Member | 52 | 28/21/28 |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 11.9 | +5.68% | 251,085 |
25/24/25 | 11.26 | +0.72% | 554,700 |
24/24/24 | 11.18 | +16.46% | 408,939 |
23/24/23 | 9.6 | +3.45% | 62,599 |
22/24/22 | 9.28 | -4.53% | 150,865 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 08:59 pm IST
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+81.13% | 111M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- DMYD B Stock